Valuation : Abivax

Market Cap 9.35B 10.89B 8.75B 8.02B 15.1B 1,040B 15.14B 104B 40.53B 524B 40.9B 40.02B 1,735B P/E 2026 *
-28.2x
P/E 2027 * -33.2x
Enterprise Value 8.25B 9.61B 7.72B 7.07B 13.32B 918B 13.36B 91.45B 35.75B 463B 36.08B 35.3B 1,531B EV / Sales 2026 *
110x
EV / Sales 2027 * 101x
Free-Float
92.81%
Yield 2026 *
-
Yield 2027 * -
1 day-0.80%
1 week-2.60%
Current month-6.73%
1 month-8.87%
3 months-12.64%
6 months-0.45%
Current year-17.65%
1 week 97.15
Extreme 97.15
104.2
1 month 97.15
Extreme 97.15
115.8
Current year 60.45
Extreme 60.45
139
1 year 60.45
Extreme 60.45
139
3 years 4.51
Extreme 4.51
139
5 years 4.51
Extreme 4.51
139
10 years 3.9
Extreme 3.9
139
Manager TitleAgeSince
Chief Executive Officer 68 2023-05-04
Director of Finance/CFO 63 2017-01-01
Chief Tech/Sci/R&D Officer - 2023-09-30
Director TitleAgeSince
Chairman 66 2022-08-15
Chairman 68 2023-05-04
Director/Board Member 60 2023-07-10
Date Insider Type Main position Quantity % Market Cap.
7/15/26 Sell

Chairman

-3,375 0.0042%
7/11/26 Fiscal year

Chief Executive Officer

17,728 0.0222%
7/11/26 Fiscal year

Chairman

12,500 0.0157%
Change 5-day change 1-year change 3-year change Capi.($)
-0.80%-2.60%+44.32%+459.54% 10.89B
-0.10%-0.95%+2.98%+23.36% 51.14B
+2.65%+4.45%+481.36%+567.32% 47.4B
+0.33%+2.47%+38.97%+19.80% 43.19B
-0.88%+0.90%+24.11%+87.74% 42.35B
-2.27%-3.02%+14.22%+51.50% 33.23B
-1.21%-0.17%+29.16%+135.38% 17.07B
-0.36%-2.14% - - 16.38B
-0.41%-0.19%+12.12%+28.35% 14.76B
+0.44%+1.70%+82.07%+47.92% 14.15B
Average -0.26%+0.54%+81.04%+157.88% 29.06B
Weighted average by Cap. -0.05%+0.99%+103.82%+156.03%

Financials

2026 *2027 *
Net sales 74.92M 87.28M 70.14M 64.23M 121M 8.34B 121M 831M 325M 4.2B 328M 321M 13.9B 82.73M 96.38M 77.46M 70.93M 134M 9.21B 134M 917M 359M 4.64B 362M 354M 15.35B
Net income -265M -309M -248M -227M -428M -29.5B -429M -2.94B -1.15B -14.87B -1.16B -1.13B -49.21B -231M -269M -216M -198M -373M -25.67B -374M -2.56B -1B -12.94B -1.01B -987M -42.82B
Net Debt -1.1B -1.28B -1.03B -945M -1.78B -123B -1.79B -12.22B -4.78B -61.82B -4.82B -4.72B -205B -993M -1.16B -929M -851M -1.6B -110B -1.61B -11B -4.3B -55.66B -4.34B -4.25B -184B
Logo Abivax
Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.
Employees
80
Date Price Change Volume
26-08-28 99.15 -0.80% 6,888
26-08-27 €99.95 -0.45% 85,504
26-08-26 €100.40 -1.86% 100,533
26-08-25 €102.30 +4.28% 190,081
26-08-24 €98.10 -3.63% 125,562
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
99.95EUR
Average target price
138.97EUR
Spread / Average Target
+39.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABVX Stock